Bhavya S Doshi, MD

faculty photo
Assistant Professor of Pediatrics (Hematology) at the Children's Hospital of Philadelphia
Department: Pediatrics
Graduate Group Affiliations

Contact information
Children's Hospital of Philadelphia
3501 Civic Center Boulevard
CTRB 5024
Philadelphia, PA 19104
Office: 267-425-7973
Fax: 215-590-3992
BS (Biology)
Emory University, 2008.
Emory University School of Medicine, 2012.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Disorders of hemostasis and thrombosis with a focus on hemophilia and inhibitor development as well as laboratory diagnosis of coagulation disorders.

Description of Research Expertise

I am a physician scientist with expertise in basic and translational approaches to improving diagnostics and therapeutics for pediatric patients with bleeding and clotting disorders. Our laboratory conducts research focused on the development, persistence, and management of alloantibodies to protein replacement therapy in hemophilia and to AAV vectors for gene therapy. Our work has identified hemophilia A patients with anti-factor VIII antibodies who may be amenable to alternative treatment modalities whether bypassing agents or immunosuppressive regimens. The aim is to identify B cell signatures that are altered in patient with alloantibody responses to therapeutics and leverage these for therapeutic development.

Selected Publications

Doshi BS, Rana J, Castaman G, Shaheen MA, Kaczmarek R, Butterfield JSS, Meeks SL, Leissinger C, Biswas M*, Arruda VR*: B cell activating factor modulates the factor VIII immune response in hemophilia A. J Clin Invest 131(8): e142906, Apr 2021.

Doshi BS, Rogers RS, Whitworth HB, Stabnick EA, Britton J, Butler RB, Obstfeld A, and Witmer CM: Utility of Repeat Testing in the Evaluation for von Willebrand Disease in Pediatric Patients. J Thromb Haemost 17(11): 1838-47, Nov 2019.

Doshi BS, Raffini LJ, George LA: Combined Anti-CD20 and mTOR Inhibition with Factor VIII for Immune Tolerance Induction in Hemophilia A Patients with Refractory Inhibitors. J Thromb Haemost 18(4): 848-852, Apr 2020.

Doshi BS, Witmer CM: Recurrence of a high titer factor VIII inhibitor in a hemophilia A patient on emicizumab prophylaxis. Haemophilia 27(4): e551-e553, Jul 2021.

Doshi BS, Kamdar A, Lambert MP, Obstfeld A: Hemolysis after medication exposure in pediatric patients with G6PD deficiency. J Pediatr Hematol Oncol 44(5): 261-263, Jul 2022.

Doshi BS, Ellison AM: Diagnosis and Management of Pediatric Venous Thromboembolism: New Therapies on the Horizon. Pediatric Emergency Care 37(5): 273-279, May 2021.

Doshi BS, Arruda VR: Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol 9(9): 273-293, Aug 27 2018.

Arruda VR, Doshi BS: Gene therapy for hemophilia: facts and quandaries in the 21st century. Mediterr J Hematol Infect Dis 12(1): e2020069, Aug 2020.

Meeks SL, Cox CL, Healey JF, Parker ET, Doshi BS, Gangadharan B, Barrow RT, Lollar P: A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood 120(12): 2512-20, Sep 2012.

Doshi BS, Gangadharan B, Doering CB, Meeks SL.: Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. PloS One 7(10): e48172, 2012.

back to top
Last updated: 07/24/2024
The Trustees of the University of Pennsylvania